Q-omics provides the consensus-scored FBXO41 profile across patient tissues and cancer cell-line models. FBXO41 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FBXO41 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, FBXO41 RNA expression shows 19,565 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, COAD, and UVM as cancer lineages where FBXO41 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO41 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO41 survival associations across molecular data types. FBXO41 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO41 RNA expression–survival associations across cancer types. High FBXO41 expression shows unfavorable associations in MESO, KIRC, ACC, LIHC and THCA, but favorable associations in HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FBXO41 RNA expression.
This table summarizes FBXO41 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FBXO41. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO41 shows higher tumor expression in COAD, HNSC, KIRC, BLCA, THCA and LUAD. The COAD box plot shows higher FBXO41 RNA expression in tumor versus normal tissue (log2 FC = +2.124, t-test p < 0.001).
This table shows molecular features associated with FBXO41 in patient tissues and cancer cell lines. In patient samples, FBXO41 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO41 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
